KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Ionis Pharmaceuticals (IONS) over the last 13 years, with Q3 2025 value amounting to $31.1 million.

  • Ionis Pharmaceuticals' Share-based Compensation fell 262.01% to $31.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $126.7 million, marking a year-over-year increase of 524.47%. This contributed to the annual value of $130.2 million for FY2024, which is 2305.19% up from last year.
  • According to the latest figures from Q3 2025, Ionis Pharmaceuticals' Share-based Compensation is $31.1 million, which was down 262.01% from $29.7 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' 5-year Share-based Compensation high stood at $37.9 million for Q1 2021, and its period low was $22.3 million during Q4 2021.
  • Over the past 5 years, Ionis Pharmaceuticals' median Share-based Compensation value was $29.7 million (recorded in 2025), while the average stood at $28.8 million.
  • In the last 5 years, Ionis Pharmaceuticals' Share-based Compensation plummeted by 7657.93% in 2021 and then soared by 3725.7% in 2024.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Share-based Compensation stood at $22.3 million in 2021, then increased by 15.41% to $25.7 million in 2022, then rose by 2.52% to $26.3 million in 2023, then surged by 37.26% to $36.1 million in 2024, then dropped by 13.84% to $31.1 million in 2025.
  • Its last three reported values are $31.1 million in Q3 2025, $29.7 million for Q2 2025, and $29.7 million during Q1 2025.